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Abstract 
Background: The infection and prevalence of extended-spectrum β-lactamases (ESBLs) is a worldwide problem, and 
the presence of ESBLs varies between countries. In this study, we investigated the occurrence of plasmid-mediated 
ESBL/AmpC/carbapenemase/aminoglycoside resistance gene expression in Escherichia coli using phenotypic and 
genotypic techniques.
Methods: A total of 58 E. coli isolates were collected from hospitals in the city of Makkah and screened for the pro-
duction of ESBL/AmpC/carbapenemase/aminoglycoside resistance genes. All samples were subjected to phenotypic 
and genotypic analyses. The antibiotic susceptibility of the E. coli isolates was determined using the Vitek-2 system 
and the minimum inhibitory concentration (MIC) assay. Antimicrobial agents tested using the Vitek 2 system and MIC 
assay included the expanded-spectrum (or third-generation) cephalosporins (e.g., cefoxitin, cefepime, aztreonam, 
cefotaxime, ceftriaxone, and ceftazidime) and carbapenems (meropenem and imipenem). Reported positive isolates 
were investigated using genotyping technology (oligonucleotide microarray-based assay and PCR). The genotyping 
investigation was focused on ESBL variants and the AmpC, carbapenemase and aminoglycoside resistance genes. 
E. coli was phylogenetically grouped, and the clonality of the isolates was studied using multilocus sequence typing 
(MLST).
Results: Our E. coli isolates exhibited different levels of resistance to ESBL drugs, including ampicillin (96.61%), 
cefoxitin (15.25%), ciprofloxacin (79.66%), cefepime (75.58%), aztreonam (89.83%), cefotaxime (76.27%), ceftazidime 
(81.36%), meropenem (0%) and imipenem (0%). Furthermore, the distribution of ESBL-producing E. coli was consist-
ent with the data obtained using an oligonucleotide microarray-based assay and PCR genotyping against genes 
associated with β-lactam resistance. ST131 was the dominant sequence type lineage of the isolates and was the most 
uropathogenic E. coli lineage. The E. coli isolates also carried aminoglycoside resistance genes.
Conclusions: The evolution and prevalence of ESBL-producing E. coli may be rapidly accelerating in Saudi Arabia due 
to the high visitation seasons (especially to the city of Makkah). The health authority in Saudi Arabia should monitor 
the level of drug resistance in all general hospitals to reduce the increasing trend of microbial drug resistance and the 
impact on patient therapy.
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Background
Gram-negative bacteria that produce β-lactamases are 
a major concern in healthcare due to their ability to 
spread globally [1]. β-lactamases are produced by bacte-
ria to hydrolyze the β-lactam ring in antibiotics, which 
results in ineffective drug treatment. Extended-spectrum 
β lactamases (ESBLs) are a major group of enzymes that 
confer resistance to several generations of β-lactam anti-
biotics, including third-generation cephalosporins [2, 3]. 
ESBL-producing Gram-negative bacteria are thought to 
be an important reason for cephalosporin therapy failure 
[4, 5]. Therefore, these bacteria should be monitored and 
reported by clinical laboratories to minimize their impact 
on patient therapy. ESBL resistance genes are primar-
ily carried by plasmids. Plasmids may also carry genes 
encoding resistance to other antibiotic classes, such as 
ampA, ampC, aminoglycosides, chloramphenicol, mac-
rolides, or quinolone. Therefore, treatment options are 
limited for bacteria that produce ESBLs due to the mul-
tiple resistance genes encoded in the plasmids. ESBL 
genes that are primarily encoded in plasmids include 
TEM, SHV, and CTX-M. Multiple variants of each gene 
are produced by altering the configuration of amino 
acids within the β-lactamase active site. Enterobacte-
riaceae, such as Klebsiella pneumoniae and Escherichia 
coli, are the major ESBL producers frequently isolated in 
clinical laboratories [6]. Acinetobacter baumannii is also 
an important ESBL-producing bacteria that has been 
reported globally [7]. Newer antibiotic classes, such as 
carbapenems, have been introduced by the pharmaceu-
tical industry as treatment options for infections caused 
by ESBL-producing bacteria. Nevertheless, carbapene-
mase-producing bacteria have also been documented [8, 
9]. Due to the increasing threat of multidrug-resistant 
bacteria, laboratory personnel, physicians, and clinical 
practitioners should implement a program to detect and 
report ESBLs as part of their infection control to limit 
the therapeutic failures caused by ESBL-producing bac-
teria. Molecular genotyping has been used concurrently 
with phenotyping techniques to detect and confirm 
antimicrobial drug resistance data and to detect Gram-
negative ESBL producing bacteria [10]. PCR, multiplex 
PCR and oligonucleotide microarray-based assays have 
been developed and used to monitor the emergence of 
ESBLs and many other drug-resistant genes from E. coli, 
K. pneumonia and A. baumannii [11–15]. Strain charac-
terization by multilocus sequence typing (MLST) is the 
method of choice in many clinical and research labora-
tories due to its high discriminatory power [16, 17]. The 
increased prevalence of ESBLs is being monitored and 
reported globally. Due to a lack of a solid data regard-
ing the emergence of ESBLs from major Saudi general 
hospitals in the region of Makkah, this study reports the 
characterization of drug resistance genes for 58 E. coli 
isolates from an in-patient ward using phenotypic and 
genotypic approaches. Understanding the phenotypic 
and molecular nature of Enterobacteriaceae during the 
busy visitation Hajj season (pilgrimage season) in the city 




A total of 58 bacterial isolates were collected from two 
different general hospitals in the city of Makkah during 
the 2014–2015 Hajj (pilgrimage) season from patients 
with urinary tract infections. The bacterial isolates were 
phenotypically and genotypically investigated in microbi-
ology laboratories at the King Abdulaziz City for Science 
and Technology (KACST). Single pure E. coli colonies 
were obtained from the all isolates. The bacteria were 
isolated from urine specimens using the clean-catch mid-
stream urine sampling technique. Urine samples were 
inoculated using a calibrated 0.01 mL urine plastic loop 
on 5% sheep blood agar and MacConkey agar plates. 
The plates were incubated at 37 °C for 24 h. Urine sam-
ples were considered positive for UTIs if the number of 
colonies equaled or exceeded 105 CFU/mL. Gram stain-
ing was performed to identify urine specimens that con-
tained more than 105  colony forming units (CFU)/mL 
of bacteria. A drop of well-mixed urine was fixed on a 
glass slide, stained, and examined under oil immersion 
(1000×) for the presence of at least one organism per oil 
immersion field.
Bacterial identification and antibiotic susceptibility testing
Bacterial identities were confirmed with a Vitek 2 GN 
ID card using the Vitek 2 system (bioMérieux, Marcy 
I’Etoile, France). Antibiotic susceptibility testing (AST) 
was completed using Vitek 2 cards (AST-N292) accord-
ing to the manufacturer’s recommendations (bioMérieux, 
Marcy I’Etoile, France). The Vitek ESBL susceptibility 
tests were interpreted according to the Clinical and Labo-
ratory Standards Institute (CLSI) criteria using the Vitek 
system. E. coli ATCC 25922 was included in each Vitek 
testing step for quality control. The minimum inhibitory 
concentrations (MICs) were determined in Mueller–Hin-
ton broth using microdilution plates [18]. The MICs of 
cefoxitin, ciprofloxacin, aztreonam, ceftazidime, mero-
penem, cefepime, cefotaxime, imipenem and ampicillin 
for all E. coli isolates were interpreted according to pre-
vious protocols (CLSI, 2014) [18]. Serial dilutions of the 
nine drugs were prepared (0.5, 1, 2, 4, 8, 16, 32, 64, 128, 
256, 512 and 1024 µg/mL) in Mueller–Hinton broth and 
added to 96-well plates. Then, the bacterial suspensions 
were added to each well to achieve a final inoculum of 
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5×105 CFU/mL. The endpoint MIC was read visually and 
by spectrophotometer at 600 nm. The lowest concentra-
tion of antibiotic that inhibited visible bacterial growth 
after 24 h at 37 °C was defined as the MIC.
Amplification and sequencing of the 16S rRNA gene
The E. coli identity was confirmed using PCR and 
sequencing of the 16S rDNA gene [19–21]. Illustra PuRe-
Taq Ready-To-Go PCR beads were used in the PCR reac-
tion (GE Health Biosciences, USA). The 25-μL reaction 
was set up as follows: 2  μL of 10  pmol of each forward 
and reverse primer (IDT, Integrated DNA Technologies) 
were used with the 8-forward primer (AGA GTT TGA 
TCC TGG CTC AG) and 805-reverse primer (GAC TAC 
CAG GGT ATC TAA TC) [22]. Exactly 1  μL of DNA 
template was added to the beads, and the reaction was 
completed using 22  μL of nuclease-free ddH2O (Pro-
mega). The amplification cycling conditions were 3  min 
for the initial incubation at 95  °C, followed by 35 cycles 
of 1 min at 95 °C, 1 min at 55 °C, and 2 min at 72 °C and 
a final extension at 72  °C for 7 min. All PCR amplicons 
were fractionated using 1% agarose gel electrophoresis 
prior to staining with ethidium bromide. Images were 
obtained with a gel documentation system under a UV 
transilluminator. The PCR amplicons were purified and 
sequenced in an ABI 3130 Genetic Analyzer (Life Tech-
nologies, Carlsbad, CA, USA) using the 16S rDNA for-
ward primer with the ABI BigDye terminator cycle 
sequencing ready reaction kit according to the manu-
facturer’s recommendations (Applied Biosystem, Foster 
City, CA, USA). The sequencing data were analyzed using 
the basic local alignment search tool BLAST-n (http://
www.ncbi.nlm.nih.gov/BLAST) or the RDP database 
[23]. Unequivocal identification was obtained using 16S 
ribosomal DNA sequences.
Genetic background grouping of E. coli strains
The genetic background grouping of the E. coli isolates 
was explored. The grouping was performed based on 
Clermont phylo-typing method [24]. The majority of 
the pathogenic extra-intestinal E. coli strains belonged 
to groups B2. In contrast, the commensal E. coli strains 
belonged to groups A, B1, C, and F. The strains were sub-
sequently phylogenetically inferred based on the pres-
ence or absence of the gene markers as follows: For group 
A, arpA+, chuA−, yjaA−, and TspE4.C2−, for group 
B1, arpA+, chuA−, yjaA−, and TspE4.C2+, for group 
F, arpA−, chuA+, yjaA−, and TspE4.C2−, for group 
B2, arpA−, chuA+, yjaA+, and TspE4.C2−, for group 
A or C, arpA+, chuA−, yjaA+, and TspE4.C2−, for 
group D or E, arpA+, chuA+, yjaA−, and TspE4.C2−. 
A standard 25-µL PCR reaction was used to investigate 
the genetic background of the E. coli strains used in our 
study. Illustra PuReTaq Ready-To-Go PCR beads were 
used in the PCR reaction (GE Health Biosciences, USA) 
as described by Clermont to amplify the arpA (400  bp) 
ChuA (288 bp), YjaA (211 bp), TspE4C2 (152 bp), and an 
internal control trpA (489 bp). Primers and PCR cycling 
conditions were described in (Table 1).
Detection of ESBL, ampC and carbapenemase genes
Global genotyping utilizing an oligonucleotide micro-
array-based assay and PCR genotyping were applied to 
identify and confirm the presence of drug resistance 
genes. For the microarray DNA analysis (Alere Technolo-
gies, Jena, Germany) [15], the ESBL/AmpC/carbapen-
emase genes were evaluated based on the manufacturer’s 
protocols (blaACC, blaACT, blaCMY, blaKHM, blaMOX-CMY9, 
blaCTX-M-1, blaCTX-M-15, blaCTX-M 2, blaCTX-M-8, blaCTX-
M-9, blaCTX-M-26, blaDHA-1, blaFOX, blaGES-1, blaG1M-1, 
blaMI-3, blaIMP, blaKPC, blaLAP-1, blaLEN-1, blaMOX, 
blaOXA-1, blaOXA-2, blaOXA-7, blaOXA-9, blaOXA-23, blaOXA-23, 
blaOXA-40, blaOXA-48, blaOXA-51, blaOXA-54, blaOXA-55, 
blaOXA-58, blaOXA-60, blaPER1, blaPER2, blaPSE-1, blaSHF-1, 
blaSHV, blaSEM-1, blaSPM-1, blaTEM, blaVEB-1, and blaVIM). 
For the PCR analysis, DNA templates were obtained by 
boiling 500 µL of bacterial cells (OD600 = 1.0) in a sterile 
single 1.5 mL Eppendorf tube in a water bath at 100 °C. 
The DNA lysate was diluted 1:10 with ddH2O and frozen 
at −20  °C before use for bacterial genotyping confirma-
tion with gene-specific primers (Table 2) [10]. The prim-
ers detected the β-lactamase genes and their variants 
(TEM, SHV, and CTX-M groups 1, 15, 2, 8, 9, and 26). 
The PCRs were performed using a 9800 Thermal Cycler 
(Applied Biosystem, USA) in a total volume of 25 µL con-
taining 10 pmol of primers, 25 µmol of dNTPs, 10 µL of 
gDNA/plasmid lysate, 2.5 µL of 10Χ Taq buffer, 2.5 mM 
MgCl2 and 2.5 U of Taq polymerase. The cycling condi-
tions used for the PCR were an initial denaturation at 
94 °C for 10 min, 35 cycles of 94 °C for 40 s, 60 °C for 40 s 
and 72 °C for 1 min and a final extension step at 72 °C for 
7 min [10]. All PCR amplicons were fractionated by 1% 
agarose gel electrophoresis prior to staining with ethid-
ium bromide. Images were obtained with a gel documen-
tation system under a UV transilluminator.
Bacterial genotyping by multilocus sequence typing
Fifty-eight E. coli isolates were subjected to multilocus 
sequence typing (MLST) as previously described [25]. The 
MLST schemes used to type E. coli were conducted using 
internal fragments of the following seven housekeeping 
genes: Adk (adenylate kinase), fumC (fumarate hydratase), 
gyrB (DNA gyrase), mdh (malate dehydrogenase), purA 
(adenylosuccinate dehydrogenase), icd (isocitrate/iso-
propylmalate dehydrogenase), recA (ATP/GTP binding 
motif ) (ID Genomics Inc, Seattle, WA, USA). The primers 
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used for amplification and sequencing are illustrated in 
(Table  3) [25]. The PCR amplifications were performed 
using a 9800 Thermal Cycler (Applied Biosystem, USA) 
with the following conditions: initial denaturation at 94 °C 
for 7 min, followed by 35 cycles of denaturation at 94 °C 
for 30 s and an annealing temperature of 56  °C for 30 s, 
extension at 72 °C for 2 min and a final 7-min extension at 
72 °C. The PCR amplicons were checked with 1% agarose 
gel electrophoresis prior to purification for sequencing. 
Forward and reverse sequencing reactions were per-
formed for every isolate. Different allele sequences were 
assigned for each locus with an arbitrary allele number for 
identification. Each bacterial isolate was characterized by 
a pattern of numbers defining its sequence type (ST). The 
sequencing data of the MLST genes were analyzed using 
the E. coli MLST Database (Warwick Medical School, 
Coventry, UK database; http://mlst.warwick.ac.uk/mlst/
dbs/Ecoli) [25]. The similarities of the allelic profiles were 
assessed using the Molecular Evolutionary Genetics Anal-
ysis (MEGA 6) software.
Phylogenetic analysis
Phylogenetic trees based on the concatenated alleles of 
seven MLST genes were constructed using the Molecular 
Evolutionary Genetics Analysis (Mega6) software for the 
E. coli dataset. The maximum likelihood trees were based 
on neighbor-joining (NJ) starting trees with Nearest-
Neighbor Interchange branch swapping. The tree stabil-
ity was assessed using the bootstrap method [26].
Results
Bacterial identification and antibiotic susceptibility testing
All obtained clinical E. coli isolates (n =  58) were phe-
notypically studied using the Vitek system and the 
microbroth dilution method to determine the MIC val-
ues against various antimicrobial drugs (cefoxitin, cipro-
floxacin, aztreonam, ceftazidime, meropenem, cefepime, 
cefotaxime, imipenem and ampicillin), (Table  4). The 
greatest number of E. coli isolates was resistant to ampi-
cillin (96.61%), followed by cefotaxime (76.27%), cefepime 
(74.58%), ceftazidime (81.36%), aztreonam (89.83%), and 
Table 1 Primer sequences and PCR conditions for quadruplex phylo-grouping of E. coli
Target gene Primer sequence Size (bp) PCR conditions Reference
arpA (phylogenetic grouping) F (5-AACGCTATTCGCCAGCTTGC-3)
R (5-TCTCCCCATACCGTACGCTA-3)
400 PCR reactions were performed in a total 
volume of 25 µL by ready-to go PCR 
beads using 20 pmol of each primers 
for all targets except arpA (40 pmol) and 
trpA (12 pmol). The cycling conditions 
were as follow: denaturation 4 min at 
94 °C, 30 cycles of 5 s at 94 °C and 20 s at 
59 °C, 20 s at 72 °C and a final extension 
step of 5 min at 72 °C
[24]
chuA (phylogenetic grouping) F (5-GACGAACCAACGGTCAGGAT-3)
R (5-TGCCGCCAGTACCAAAGACA-3)
288
yjaA (phylogenetic grouping) F (5-TGAAGTGTCAGGAGACGCTG-3)
R (5-ATGGAGAATGCGTTCCTCAAC-3)
211
TspE4C2 (phylogenetic grouping) F (5-GAGTAATGTCGGGGCATTCA-3)
R (5-GCGCCAACAAAGTATTACG-3)
152
Internal control trpA  F (5-CGGCGATAAAGACATCTTCAC-3)
R (5-GCAACGCGGCCTGGCGGAAG-3)
489
Table 2 Multiplex PCR-specific primers for ESBL gene detection in Enterobacteriacaea
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cefoxitin (15.25%). Meropenem and imipenem had rates 
of 0%, and the non-β-lactam ciprofloxacin had a rate of 
79.66%. All E. coli isolates were sensitive to meropenem 
and imipenem (Fig. 1).
ESBL-producing E. coli genotyping
The genotyping of ESBL-producing E. coli isolates by 
the global analysis of an oligonucleotide microarray-
based assay and PCR identified a high proportion 
of β-lactamase genes among the E. coli isolates. The 
blaCTX-M1, blaCTX-M15, blaOXA1 and blaTEM gen-
otypes were more frequently identified and were more 
predominant among the E. coli isolates than the blaCTX-
M, blaOXA and blaSHV variants. The prevalence was 
46.7% for blaCTX-M1 and blaCTX-M15, 48.3% for 
blaOXA1, and 38.7% for blaTEM. The genotypic preva-
lence of blaSHV was 3.2% among all isolates, which was 
considerably lower than the prevalence for blaCTX-M1, 
blaCTX-M15, blaOXA1 and blaTEM. No carbapenem-
resistant E. coli isolate was detected (Fig. 2).
Distribution of ESBL genes in E. coli
The β-lactam genes were studied to evaluate the distri-
bution of the genes among our isolates. We found that 
13.7% (8/58) of the E. coli isolates harbored four major 
ESBL genes (blaCTX-M1, blaCTX-M15, blaOXA1, and blaTEM) 
and 17.2% (10/58) contained three ESBL genes (blaCTX-
M1, blaCTX-M15, and blaOXA1). Additionally, two posi-
tive ESBL genotypes (3.4%; 2/58) contained blaOXA1 and 
blaTEM and two isolates contained only blaSHV (3.4%; 
2/58). No carbapenemase genes were detected among 
the isolates according to the phenotypic and genotypic 
testing.
The phylogenetic grouping of E. coli strains
The genetic background grouping of the E. coli isolates 
was assigned based on the Clermont method which 
is very specific for E. coli phylo-typing groups [24]. It 
has shown that 46.55% (27) of the ESBL-producing E. 
coli isolate collection belonged to group B2, and 6.9% 
(4) belonged to group D or E, while 12% (7) belonged 
to group B1, 3.4% (2) belonged to group A, 24% (14) 
belonged to group A or C and 6.9% (4) belonged to group 
F. The majority of the pathogenic extra-intestinal E. coli 
strains belonged to groups B2 (Fig. 3).
Prevalence of genes associated with aminoglycoside 
resistance in the E. coli isolates
The prevalence of genes associated with aminoglycoside 
resistance among the 58 E. coli isolates was investigated. 
A total of 44.8% of the E. coli isolates carried the aac6 
gene, 43% harbored aac6Ib, 42% contained aadA4, and 
36% contained strB; these prevalences represented high 
proportions and were more common than the other ami-
noglycoside genes (15% for aadA1, 12% for aadA2, 4% for 
aadB, 4% for ant2, 12% for aphA and 1% for strA) (Fig. 4).
Bacterial genotyping by MLST
In this study, 58 E. coli isolates were assigned sequence 
types (ST) and ST complexes (STc) using a standard 
multi-locus sequence typing method (Fig. 5) [25]. Of the 
58 E. coli isolates, 7 isolates (12%) belonged to STc 10, 20 
isolates (34.5%) to STc 131, and 4 isolates (7%) to STc 648 
and STc 38. Other ST complexes (46, 448, 156, 155, 23, 12 
and 73) were represented by 1–3 isolates (2–5%). The ST 
complex could not be determined for 14 isolates (24%). A 
new allele of the recA gene was identified in isolate ID 4. 
This allele had one nucleotide substitution compared to 
allele 2 at position 40 from the beginning of the allele (C 
substituted by T). The allelic profile of one isolate (isolate 
ID 12) was not previously reported (Fig. 5).
Phylogenetic analysis
We conducted a phylogenetic analysis to examine the 
clonal diversity and phylogenetic relationships among 
the E. coli isolates. The E. coli isolates clustered in sev-
eral monophyletic clades that corresponded to known 
phylogenetic groups. The majority of the E. coli isolates 
fell into the phylogenetic groups B2: ST131 (20 isolates), 
ST1193 (3 isolates) [27], ST73 (1 isolate), ST12 (1 iso-
late) and ST127 (1 isolate). In this study, four E. coli iso-
lates appeared to belong to group E: ST38 (3 isolates) [27] 
ST315 (1 isolate), of which all isolates were from STc 38. 
Of the rest, one isolate belonged to phylogroup A, thir-
teen to phylogroup C, eight to phylogroup B1, two to phy-
logroup C, and four to phylogroup F. Most of the known 
virulent extraintestinal strains primarily belong to group 
Table 3 Primers used to  amplify and  sequence the seven 
housekeeping genes in  the E. coli isolates for  the MLST 
analysis
Gene Primer sequences Usage
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MIC MIC MIC MIC MIC MIC MIC MIC MIC
1059 8 32 256 128 1024 1024 <0.5 <0.5 >1024
1129 8 <0.5 <0.5 <0.5 <0.5 16 <0.5 <0.5 1024
1060 4 64 64 64 >1024 >1024 <0.5 <0.5 >1024
1097 4 64 128 32 >1024 <0.5 <0.5 <0.5 >1024
4110 8 8 128 16 64 32 <0.5 <0.5 1024
7055 1 16 <0.5 32 1024 1 <0.5 <0.5 >1024
1015 16 16 32 8 64 1024 <0.5 <0.5 512
2001 4 <0.5 128 64 1024 64 <0.5 <0.5 >1024
1114 8 256 512 128 >1024 128 <0.5 <0.5 >1024
1007 8 16 128 32 128 128 <0.5 <0.5 >1024
1111 256 128 128 128 >1024 64 <0.5 <0.5 >1024
1128 16 16 64 16 256 1024 <0.5 <0.5 1024
1005 4 4 64 16 1024 16 <0.5 <0.5 >1024
1116 8 16 32 8 >1024 64 <0.5 <0.5 >1024
1010 2 <0.5 <0.5 <0.5 2 32 <0.5 <0.5 >1024
1041 512 1024 >1024 1024 >1024 1024 <0.5 1 >1024
1089 8 128 128 32 1024 64 <0.5 <0.5 >1024
1031 16 32 128 32 256 32 <0.5 <0.5 >1024
1055 16 256 256 256 >1024 1024 <0.5 <0.5 >1024
1057 16 64 512 128 1024 1024 <0.5 <0.5 >1024
1075 8 8 512 64 32 64 <0.5 <0.5 1024
1065 8 128 512 256 1024 <0.5 <0.5 <0.5 >1024
1085 32 64 64 16 512 64 <0.5 <0.5 >1024
1053 16 256 512 128 >1024 1024 <0.5 <0.5 >1024
1054 32 256 256 128 >1024 1024 <0.5 <0.5 >1024
1013 16 16 64 32 512 16 <0.5 <0.5 >1024
1011 16 64 256 64 1024 1024 <0.5 <0.5 >1024
1034 16 64 256 128 256 128 <0.5 <0.5 >1024
1028 8 32 256 64 512 <0.5 <0.5 <0.5 >1024
1045 16 4 128 8 32 1024 <0.5 <0.5 1024
1118 32 32 128 32 256 1024 <0.5 <0.5 1024
1096 1 <0.5 >1024 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
1110 8 128 256 64 512 1024 <0.5 <0.5 >1024
1025 8 16 >1024 32 256 32 <0.5 <0.5 >1024
1016 16 16 128 64 256 16 <0.5 <0.5 >1024
4003 8 16 256 64 512 1024 <0.5 <0.5 >1024
90003 32 128 >1024 512 >1024 64 <0.5 <0.5 >1024
1020 128 <0.5 4 32 8 <0.5 <0.5 <0.5 >1024
1094 16 32 256 64 512 64 <0.5 <0.5 >1024
1019 8 128 >1024 512 >1024 64 <0.5 <0.5 >1024
1012 16 <0.5 <0.5 4 <0.5 32 <0.5 <0.5 8
2002 8 16 1024 32 256 32 <0.5 <0.5 >1024
4045 8 8 128 32 256 64 <0.5 <0.5 >1024
1081 8 32 256 32 512 1024 <0.5 <0.5 >1024
1018 4 32 128 64 1024 <0.5 <0.5 <0.5 >1024
3043 4 <0.5 <0.5 <0.5 <0.5 16 <0.5 <0.5 1024
1091 16 128 512 256 >1024 1024 <0.5 <0.5 >1024
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B2 and to a lesser extent to group D or E (4). Group A 
together with group B1, F, and C are considered predomi-
nant among commensal E. coli strains (5).
Discussion
During congested visitation seasons, especially dur-
ing the religious pilgrimage (Hajj), the risk of spreading 
multidrug-resistant microbes increases substantially 
[28]. Therefore, this study investigated the prevalence of 
ESBL-producing E. coli in local general hospitals in Mak-
kah during Hajj and the correlation between the ESBL 
phenotype and antimicrobial drug resistance using geno-
typing approaches. This study also explored multilocus 
sequence typing (MLST) to characterize these isolates 
and to enhance our understanding of the epidemiology of 
ESBL-producing E. coli in our region. Our data had dem-
onstrated that our E. coli isolates exhibited varying levels 
of resistance to ESBL drugs and carried genes associated 
with aminoglycoside resistance. No carbapenem resist-
ance genes were identified in any of the collected and 
investigated E. coli isolates (n =  58). All uropathogenic 
E. coli isolates in this study are classified as multidrug-
resistant (MDR) according to the criteria by Magiorakos 
[29].
The distribution of ESBL-producing E. coli was con-
sistent with the data obtained from an oligonucleotide 
microarray-based assay and PCR genotyping against 
genes associated with β-lactam resistance. The dominant 





























MIC MIC MIC MIC MIC MIC MIC MIC MIC
3067 32 <0.5 16 64 64 <0.5 <0.5 <0.5 >1024
2003 16 64 256 64 512 4 <0.5 <0.5 >1024
1103 32 32 16 2 64 1024 <0.5 <0.5 >1024
1120 16 32 64 32 256 32 <0.5 <0.5 >1024
1119 8 64 256 64 1024 1024 <0.5 <0.5 >1024
1098 8 8 128 32 128 64 <0.5 <0.5 1024
1124 8 64 512 256 1024 32 <0.5 <0.5 >1024
1104 16 16 16 1 64 <0.5 <0.5 <0.5 >1024
1125 8 32 128 64 512 <0.5 <0.5 <0.5 >1024
1102 8 64 256 64 512 128 <0.5 <0.5 >1024
1117 16 128 256 128 1024 <0.5 <0.5 <0.5 >1024
1105 8 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 >1024
Fig. 1 The level of E. coli resistance (in percentages) compared with 
the major ESBL drugs based on the MIC tests. No carbapenase phe-
notype was detected but Ciprofloxacin-resistance (fluoroquinolone 
resistance) was identified among the E. coli isolates
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the most uropathogenic E. coli lineage. The most com-
monly isolated bacterium from patients with urinary 
tract infections is E. coli. These isolates usually harbor 
different plasmids. Therefore, they have a tendency to 
acquire multidrug-resistant phenotypes and are difficult 
to treat.
Consistent with our study, studies have associated 
ST131/CTX-M15 human uropathogenic E. coli with 
ST410/CTX-M15, and ST648/CTX-M15. However, it 
was shown that ST410/CTX-M15, and ST648/CTX-M15 
were also isolated from uropathogenic E. coli of cats and 
dogs (feline and canine) in Switzerland [30, 31]. These 
circulating STs may suggest that disease transmission 
between companion animals and humans may occur 
by direct contact. Furthermore, three isolates of E. coli 
ST1193 were evident in this study. E. coli ST1193 is asso-
ciated with urinary tract infection and fluoroquinolone-
resistance, namely ciprofloxacin-resistance (Figs.  1, 5) 
[32, 33]. E. coli ST1193 may also be transmitted through 
household contact as suggested by a study from Japan 
[34].
It was demonstrated that multidrug-resistance (MDR) 
E. coli clone ST131 was globally disseminated in six dif-
ferent geographical countries. The rapid spread and 
emergence among countries may be due to high viru-
lence factor gene-content, the presence of ESBL CTX-M-
15, and fluoroquinolones resistance. Notably, the E. coli 
clone ST131 fluoroquinolone resistance phenotype was 
Fig. 2 The distribution of the 58 ESBL-producing E. coli isolates investigated via oligonucleotide microarray-based assay and PCR genotyping 
against genes associated with β-lactam resistance
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Fig. 3 a Quadruples PCR profiles of 58 E. coli MDR isolates. Isolate IDs shown under each lane. Data assignment were performed according to 
the presence or absence of signals of the following gene order arpA, chuA, yjaA, TspE4.C2. Row 1, lanes 1, 12—group A (+−−−); lanes 2–11, 13, 
15—groups A or C (+−+−), lanes 16–22—group B1 (+−+), lane 14—group B2 (−+++), lanes 23–24—group F (−+−); Row 2, lanes 1–2—group 
F (−+−), lanes 3–24—group B2 (−+++) or (−++−) in lane 7; Row 3, lanes 1–4—group B2 (−+++), lanes 5–8—groups E or D (++−+), lanes 
9–10—groups A or C (+−+−). b Groups A/C differentiation. In all lanes, both bands for internal control and Group C specific trpA fragment 
(219 bp) are present. c Groups D/E differentiation. Lanes 1, 3 and 4—both bands for internal control and Group E specific arpA fragment (301 bp) are 
present. Lane 2—only internal control present
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the most prevalent geographically and was detected in 
this current study in Saudi Arabia (Figs. 1, 5) [35].
Studies have shown that pathogenicity island acqui-
sition by uropathogenic E. coli may worsen urinary 
tract infections and aid in evasion of the host immune 
response, resulting in spreading in the bloodstream. 
Gene acquisition by intestinal pathogenic bacteria pro-
motes their colonization in different intestinal regions; 
these genes may also alter the mechanism of bacterial-
host interactions, causing distinct gastrointestinal pathol-
ogy [27]. It was shown that a urinary sepsis niche for E. 
coli ST131 compared to bacteremia in non-ST131 E. coli 
clones [32, 36]. However, this niche could not be linked 
to the clinical manifestation of renal tract infections in 
humans. No clinical focus to other sites of infection, such 
as intra-abdominal abscess, ascitic fluid, bones/joints, 
respiratory tract or bacteremia, has been established for 
the ST131 clone [37, 38]. There is evidence for a direct 
human-to-human route of transmission for ST131. For 
instance, an elderly father with pyelonephritis transmit-
ted ST131 E. coli to his daughter, which initiated a similar 
illness in her. Similarly, an identical clone was identified 
from a young child with osteoarticular infection and a 
fecal sample from his mother [39, 40]. ST131 may contain 
genes for multiple antimicrobial resistance mechanisms, 
which may make therapy difficult. Carbapenems alone 
or in combination with amikacin were successfully used 
to treat infections caused by clones harboring CTX-M 
genes [32, 39]. A study demonstrated ESBL-producing E. 
coli acquisition among Makkah visitors after the Hajj (pil-
grimage) season, especially CTX-M genes [28].
Molecular epidemiological studies have focused on the 
characterization and spread of the ST131 clone; however, 
global studies on the distribution and spread between 
humans and animals are limited, particularly in the devel-
oping world. There is a high frequency of infection by the 
drug-resistant ST131 clone in developing countries and a 
lack of timely countermeasures resulting in high morbid-
ity and mortality rates [41–43].
Conclusion
In this study, 58 E. coli isolates were collected from 
patients with urinary tract infections from two local hos-
pitals in the city of Makkah during the 2014–2015 Hajj 
(pilgrimage) season and screened for the production of 
ESBL/AmpC/carbapenemase/aminoglycoside resist-
ance genes using phenotypic and genotypic analyses. Our 
data had demonstrated that our isolates primarily car-
ried various ESBL and aminoglycoside resistance genes. 
The dominant sequence type lineage of the isolates was 
ST131, which was the most uropathogenic E. coli line-
age. A genetic analysis of multiple isolates from the Mid-
dle Eastern regions may contribute to the development of 
rapid molecular detection methods and may lead to new 
therapies. Furthermore, controlling the endemicity of 
emerging MDR and decreasing the occurrence and preva-
lence of drug-resistant uropathogenic E. coli during heavy 
visitation seasons in the city of Makkah may involve the 
implementation of a stringent antidrug treatment policy.
Fig. 4 Prevalence of genes associated with aminoglycoside resist-
ance
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